Pennant Group Gestion
Gestion contrôle des critères 3/4
Le PDG Pennant Group est Brent Guerisoli, nommé en Aug2022, a un mandat de 3.5 ans. La rémunération annuelle totale est $ 3.74M, composée du salaire de 11.9% et des bonus 88.1%, y compris les actions et options de la société. détient directement 0.3% des actions de la société, d'une valeur de $ 4.05M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.8 ans et 6.1 ans.
Informations clés
Brent Guerisoli
Directeur général
US$3.7m
Rémunération totale
| Pourcentage du salaire du PDG | 11.89% |
| Durée du mandat du directeur général | 4yrs |
| Propriété du PDG | 0.3% |
| Durée moyenne d'occupation des postes de direction | 3.8yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 6.1yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Jul 30
PNTG: Sector Demand Tailwinds And Index Inclusion Will Support Future Upside
The Pennant Group analyst price target has moved from $40 to $49 as analysts point to updated assumptions on revenue growth, profit margins, and sector demand trends to support the higher valuation range. Analyst Commentary on Pennant Group Recent research updates on Pennant Group highlight a more constructive tone from bullish analysts who are revisiting their valuation work ahead of upcoming earnings.
Mise à jour du récit • Jul 16
PNTG: Sector Tailwinds And Tech Investments Are Expected To Support Steady Upside
The analyst price target for Pennant Group has increased from $40.83 to $43.50. Analysts attribute this change to supportive sector trends in healthcare services, anticipated demand for care, and ongoing investments in growth and technology, which are key drivers behind their updated assumptions.Mise à jour du récit • Jul 02
PNTG: Q1 Senior Health Momentum And Expansion Are Expected To Support Upside
The Pennant Group analyst price target has increased by about $2.70 to roughly $40.83. Analysts attribute the change to updated views on fair value, profitability, and valuation multiples, following recent research from firms that raised their targets by $2, $3, and $6.Article d’analyse • Jun 21
Pennant Group (PNTG) Stock Could Be 12.4% Undervalued After Q1 Revenue Beat
Pennant Group (PNTG) is back in focus after reporting quarterly revenue growth of more than 35% year over year, alongside higher net profit, beating analyst expectations and drawing fresh attention to its decentralized operating model. See our latest analysis for Pennant Group. The recent Q1 surprise and focus on Pennant Group’s decentralized model come against a backdrop of building momentum, with a year to date share price return of 20.16% and a 3 year total shareholder return of 174.55%,...
Mise à jour du récit • Jun 18
PNTG: Senior Health Momentum And Hartford Partnership Will Drive Future Stock Upside
Analysts have raised their price target on Pennant Group stock by a combined $11, citing updated views on the company supported by recent research from multiple firms. Analyst Commentary Recent research on Pennant Group stock points to a more nuanced view than the headline price target increases suggest.Mise à jour du récit • Jun 04
PNTG: Senior Living Expansion And Higher P/E Assumptions Will Support Future Upside Potential
Narrative Update on Pennant Group The analyst fair value estimate for Pennant Group has moved from $36.00 to $40.00, with analysts pointing to updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers for the new price targets. Analyst Commentary Recent Street research around Pennant Group has centered on updated price targets that reflect revised assumptions for revenue, profitability, and the P/E multiple applied to future earnings.Mise à jour du récit • May 06
PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential
Analysts have raised Pennant Group's fair value estimate by $2 to $36, reflecting updated Street price targets and ongoing confidence that the company can gradually realize earnings potential from the AMED assets over time. Analyst Commentary Recent Street research has centered on how quickly Pennant Group can translate the AMED assets into consistent earnings and whether current valuation fairly reflects that path.Mise à jour du récit • Apr 22
PNTG: AMED Assets Are Expected To Underpin Future Upside Despite 2026 Guidance
Narrative Update Analysts have nudged Pennant Group's price target higher, with recent moves such as RBC Capital's increase to $41 from $39 contributing to a modest lift in estimated fair value and future P/E assumptions. Analyst Commentary Recent Street research around Pennant Group centers on how the market should weigh its guidance against longer term earnings potential from AMED assets and what that could imply for valuation.Mise à jour du récit • Apr 07
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Guidance
Narrative Update on Pennant Group Analysts have lifted Pennant Group's price targets into a $38 to $41 range, citing long-term earnings potential tied to AMED assets. They also hold a relatively favorable view of Medicare Advantage exposure, even with mixed near term guidance and sector headwinds.Mise à jour du récit • Mar 24
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Outlook
Narrative Update Analysts have recently nudged Pennant Group's average price target higher into the high $30s to low $40s range, citing confidence that the company can gradually realize earnings potential from the AMED assets, even though 2026 adjusted EBITDA guidance sits below earlier expectations. Analyst Commentary Recent research updates show analysts adjusting expectations for Pennant Group while still assigning higher price targets.Mise à jour du récit • Mar 10
PNTG: AMED Earnings Potential Will Offset Tempered Outlook For 2026
Pennant Group's updated fair value estimate edges up to about $37.83 from $37.50 as analysts lift price targets into the high $30s and low $40s, pointing to confidence in long term earnings potential from AMED assets, despite more tempered revenue growth assumptions and a slightly lower future P/E multiple. Analyst Commentary Recent research points to a generally constructive view on Pennant Group, with price targets shifting into the high $30s and low $40s range.Mise à jour du récit • Feb 24
PNTG: Fair Outlook Will Weigh Medicare Advantage Constructiveness Against Policy And Margin Risks
Analysts have raised their price target on Pennant Group from $31 to $38, with the higher fair value of $34 linked to updated views on revenue growth, profit margin, and a higher future P/E multiple in the context of a relatively constructive stance on Medicare Advantage. Analyst Commentary Even with the higher price target range and a constructive stance on Medicare Advantage, some commentary around Pennant Group points to risks that are worth keeping in mind as you weigh the setup.Mise à jour du récit • Feb 10
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Narrative Update on Pennant Group Analysts have raised their price target on Pennant Group to $38 from $31, citing potential upside from home health reimbursement rates even under conservative assumptions, and noting that recent regulatory concerns are already reflected in the shares. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the shares even when they assume conservative home health reimbursement rates, which they view as already reflected in the current valuation.Article d’analyse • Jan 28
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Mise à jour du récit • Jan 26
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Analysts have lifted their price target on Pennant Group to US$38 from US$31, citing potential upside from home health reimbursement rates even under conservative assumptions. They also view the current valuation as offering attractive optionality if reimbursement trends improve.Mise à jour du récit • Jan 11
PNTG: Raised Fair Value Framework Will Rely On Home Health Reimbursement Outcomes
Analysts have raised their price target on Pennant Group from $31 to $38, citing updated fair value assumptions of $37.50, a higher future P/E estimate of 27.33, and expectations for stronger revenue growth, while also accounting for a slightly higher discount rate and a modestly lower profit margin outlook. Analyst Commentary Recent Street research provides a mix of optimism and caution around Pennant Group, with updated targets and ratings reflecting changing views on reimbursement, valuation, and sector risk.Mise à jour du récit • Dec 16
PNTG Will Balance Reimbursement Upside Against Policy And Margin Execution Risks
Pennant Group's analyst price target has been raised from $28 to $30 per share, as analysts highlight upside from potential home health reimbursement improvements despite conservative base case assumptions. Analyst Commentary While the latest target increase underscores growing optimism around home health reimbursement, not all market observers share an unequivocally bullish stance.Article d’analyse • Aug 09
The Pennant Group, Inc. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
NasdaqGS:PNTG 1 Year Share Price vs Fair Value Explore Pennant Group's Fair Values from the Community and select yours...Article d’analyse • Jul 17
Earnings Tell The Story For The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 32.2x might make it look like a strong...Article d’analyse • Jun 28
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • May 16
Pennant Group's (NASDAQ:PNTG) Earnings Are Weaker Than They Seem
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock was strong after they recently reported robust earnings. However, our...Article d’analyse • Apr 15
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 33% Discount?
Key Insights Pennant Group's estimated fair value is US$38.66 based on 2 Stage Free Cash Flow to Equity Pennant Group...Article d’analyse • Mar 01
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Article d’analyse • Dec 21
Why Investors Shouldn't Be Surprised By The Pennant Group, Inc.'s (NASDAQ:PNTG) P/E
With a price-to-earnings (or "P/E") ratio of 44.5x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...Article d’analyse • Nov 14
Investors Shouldn't Be Too Comfortable With Pennant Group's (NASDAQ:PNTG) Earnings
Unsurprisingly, The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock price was strong on the back of its healthy earnings...Article d’analyse • Nov 12
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 34% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pennant Group fair value estimate is US$50.94 Current share...Article d’analyse • Oct 06
Is Now The Time To Put Pennant Group (NASDAQ:PNTG) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Nouveau récit • Sep 16
Critical Acquisitions And Leadership Drive Remarkable Growth In Home Health Sector
Emphasis on expansion and acquisitions, such as the Muir Home Health joint venture, aims to significantly boost revenue and market share.Article d’analyse • Sep 14
Investors Still Waiting For A Pull Back In The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 53.9x might make it look like a strong...Article d’analyse • Aug 26
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • May 14
Here's Why Pennant Group (NASDAQ:PNTG) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$32m |
| Mar 31 2026 | n/a | n/a | US$30m |
| Dec 31 2025 | US$4m | US$445k | US$30m |
| Sep 30 2025 | n/a | n/a | US$27m |
| Jun 30 2025 | n/a | n/a | US$27m |
| Mar 31 2025 | n/a | n/a | US$25m |
| Dec 31 2024 | US$3m | US$415k | US$23m |
| Sep 30 2024 | n/a | n/a | US$21m |
| Jun 30 2024 | n/a | n/a | US$19m |
| Mar 31 2024 | n/a | n/a | US$16m |
| Dec 31 2023 | US$2m | US$363k | US$13m |
| Sep 30 2023 | n/a | n/a | US$13m |
| Jun 30 2023 | n/a | n/a | US$13m |
| Mar 31 2023 | n/a | n/a | US$7m |
| Dec 31 2022 | US$2m | US$296k | US$7m |
| Sep 30 2022 | n/a | n/a | US$1m |
| Jun 30 2022 | n/a | n/a | -US$3m |
| Mar 31 2022 | n/a | n/a | US$3m |
| Dec 31 2021 | US$760k | US$268k | US$3m |
| Sep 30 2021 | n/a | n/a | US$9m |
| Jun 30 2021 | n/a | n/a | US$12m |
| Mar 31 2021 | n/a | n/a | US$14m |
| Dec 31 2020 | US$2m | US$228k | US$16m |
| Sep 30 2020 | n/a | n/a | US$8m |
| Jun 30 2020 | n/a | n/a | US$5m |
| Mar 31 2020 | n/a | n/a | US$4m |
| Dec 31 2019 | US$605k | US$55k | US$3m |
Rémunération vs marché: La rémunération totale de Brent ($USD 3.74M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 5.15M ).
Rémunération et revenus: La rémunération de Brent a augmenté de plus de 20 % au cours de l'année écoulée.
PDG
Brent Guerisoli (45 yo)
4yrs
Titularisation
US$3,739,476
Compensation
Mr. Brent J. Guerisoli is Chairman of the Board at The Pennant Group, Inc. from January 1, 2025 and has been its Chief Executive Officer since August 01, 2022. Mr. Guerisoli serves as a Director at The Pen...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Chairman | 4yrs | US$3.74m | 0.30% $ 4.0m | |
| President & COO | 7.6yrs | US$3.39m | 0.44% $ 6.0m | |
| Chief Financial Officer | 3.3yrs | US$2.66m | 0.049% $ 661.2k | |
| Executive VP | 3.6yrs | US$1.80m | 0.060% $ 819.2k | |
| Chief Clinical Officer | no data | US$1.83m | 0.049% $ 668.7k | |
| President of Pinnacle Senior Living LLC | no data | pas de données | pas de données |
3.8yrs
Durée moyenne de l'emploi
44yo
Âge moyen
Gestion expérimentée: L'équipe de direction de PNTG est considérée comme expérimentée (ancienneté moyenne 3.8 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Chairman | 3.5yrs | US$3.74m | 0.30% $ 4.0m | |
| Independent Director | 5.3yrs | US$251.69k | 0.29% $ 4.0m | |
| Lead Independent Director | 7.6yrs | US$313.43k | 0.17% $ 2.3m | |
| Independent Director | 6.8yrs | US$259.19k | 0.51% $ 6.9m | |
| Independent Director | 7.6yrs | US$236.69k | 2.2% $ 30.0m | |
| Independent Director | 7.6yrs | US$242.19k | 0.13% $ 1.7m | |
| Independent Director | 1.3yrs | US$123.47k | 0.66% $ 9.0m | |
| Independent Director | 4.6yrs | US$248.69k | 0.11% $ 1.5m |
6.1yrs
Durée moyenne de l'emploi
63yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de PNTG sont considérés comme expérimentés (ancienneté moyenne 6.1 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/08 13:13 |
| Cours de l'action en fin de journée | 2026/08/07 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
The Pennant Group, Inc. est couverte par 8 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Brian Tanquilut | Jefferies LLC |
| Michael Wiederhorn | Oppenheimer & Co. Inc. |
| Benjamin Hendrix | RBC Capital Markets |